{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061552","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.094410+00:00","generated_at":"2026-06-08T07:00:16.362226+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PMV Pharma reports Q3 loss, PC14586 Phase 1 data shows 38% ORR at RP2D","bullets":["Net loss 9mo $53.2M vs $54.0M YoY; cash $238.1M as of Sep 30, 2023.","PC14586 PYNNACLE: 38% ORR at 2000 mg RP2D (6/16 evaluable, TP53 Y220C/KRAS wild-type).","Median duration of response 7 months across ovarian, breast, prostate, SCLC, endometrial cancers.","Registrational Phase 2 trial to start Q1 2024; RP2D aligned with FDA in Q3 2023 meeting.","Raised $35.1M net via ATM facility during 9mo; R&D expenses increased to $42.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061552","json":"https://secwatch.observer/filing/0000950170-23-061552.json","markdown":"https://secwatch.observer/filing/0000950170-23-061552.md","text":"https://secwatch.observer/filing/0000950170-23-061552.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000095017023061552/0000950170-23-061552-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000095017023061552/pmvp-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:00:16.362226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77212af6ee9340d29e6dfafa8d0412a14b1920c8","claim":"PMV Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000095017023061552/0000950170-23-061552-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}